Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk.
AIDS
; 38(11): 1722-1724, 2024 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-39088829
ABSTRACT
This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96âweeks of rosuvastatin on pulse wave velocity (PWV) in men (nâ=â55, 54âyears) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54âm/s standard error of difference (SED) 0.26] and placebo [0.50âm/s (SED 0.26), Pâ=â0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40âm/s (SE 0.31); placebo 9.21âm/s (SE0.31), Pâ=â0.676].
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Infecções por HIV
/
Análise de Onda de Pulso
/
Rosuvastatina Cálcica
Limite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
AIDS
/
AIDS (Lond.)
/
AIDS (London, England)
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Reino Unido